Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 21, 2022 - Issue 11
Submit an article Journal homepage
494
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Real-world practice patterns and characteristics of adverse events with selexipag in Korean patients with pulmonary arterial hypertension

Sung-A Changa Division of Cardiology, Department of Medicine, Heart Vascular and Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaView further author information
,
Sang Hyun Leeb Division of Cardiology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan, Republic of KoreaView further author information
,
Jung Hyun Choic Division of Cardiology, Department of Internal Medicine, Pusan National University Hospital, Pusan, Republic of KoreaView further author information
,
Wook-Jin Chungd Division of Cardiology, Department of Medicine, Gachon University Gil Medical Center, Incheon, Republic of KoreaView further author information
,
Jae Young Choie Division of Pediatric Cardiology, Congenital Heart Disease Center, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of KoreaView further author information
,
Hyung-Kwan Kimf Division of Cardiology, Department of Internal Medicine Seoul National University College of Medicine, Section of Cardiovascular Imaging, Cardiovascular Center, Seoul National University Hospital, Seoul, Republic of KoreaView further author information
,
Hae-Ok Jungg Division of Cardiology, Department of Medicine, The Catholic University of Korea Seoul St. Mary’s Hospital, Seoul, Republic of KoreaView further author information
,
Seong-Mi Parkh Division of Cardiology, Korea University Medicine, Anam hospital, Seoul, Republic of KoreaView further author information
,
Won-Jang Kimi Division of Cardiology, Department of Cardiology, CHA Bundang Medical Center, CHA University School of Medicine, Republic of KoreaView further author information
,
Su Young Jungj Medical Affairs, Janssen Korea Ltd, Seoul, Republic of KoreaView further author information
&
Hyuk-Jae Changk Division of Cardiology, Severance Cardiovascular Hospital, Yonsei College of Medicine, Seoul, Republic of KoreaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6139-7545View further author information
ORCID Icon show all
Pages 1423-1432 | Received 28 Feb 2022, Accepted 20 Apr 2022, Published online: 28 Apr 2022

References

  • McLaughlin VV, Suissa S. Prognosis of pulmonary arterial hypertension: the power of clinical registries of rare diseases. Am Heart Assoc. 2010;122(2):106–8.
  • Oudiz RJ. Death in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine. 2013;188(3):269–70.
  • Song S, Lee S-E, Oh SK, et al. Demographics, treatment trends, and survival rate in incident pulmonary artery hypertension in Korea: a nationwide study based on the health insurance review and assessment service database. PloS one. 2018;13(12):e0209148.
  • Beshay S, Sahay S, Humbert M. Evaluation and management of pulmonary arterial hypertension. Respir Med. 2020;171:106099.
  • Levine DJ. Pulmonary arterial hypertension: updates in epidemiology and evaluation of patients. Am J Manag Care. 2021;27(3 Suppl):S35–S41.
  • Lang IM, Gaine SP. Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension. Eur Respir Rev. 2015;24(138):630–641.
  • Rothman A, Cruz G, Evans WN, et al. Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension. Pulm Circ. 2020;10(1):2045894019876545.
  • Simonneau G, Torbicki A, Hoeper MM, et al., Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012;40(4):874–880.
  • Sitbon O, Channick R, Chin KM, et al., Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522–2533.
  • Rubin LJ. Pathology and pathophysiology of primary pulmonary hypertension. Am J Cardiol. 1995;75(3):51A–54A.
  • Kim NH, Hemnes AR, Chakinala MM, et al., Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE. J Heart Lung Transplant. 2021;40(4):279–288.
  • Gaine S, Sitbon O, Channick R, et al. The Impact of Time from Diagnosis at Baseline on Long-Term Outcome in the GRIPHON Study: Selexipag in Pulmonary Arterial Hypertension. Proceedings of American Thoracic Society 2019 International Conference;2019 May 17-22;Dallas, TX: ATS; 2019. p. A2502–A2502.
  • Holthaus N, Prins KW, Rose L, et al. Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients. Pulm Circ. 2019;9(3):2045894019862167.
  • Galie N, Hoeper MM, Humbert M, et al., Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30(20):2493–2537.
  • Actelion Pharmaceuticals US Inc (2015) UPTRAVI (selexipag) tablets, for oral use [Internet]. cited 15 Sept 2021]. Available from 2021 Sept 15: http://www.fda.gov/.
  • International Conference on Harmonisation: clinical safety data management: definitions and standards for expedited reporting: E2A. [Internet]. cited 2021 Sept 15]. Available from 2021 Sept 15: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2B/Step4/E2B_R2__Guideline.pdf.
  • Tanabe N, Ikeda S, Tahara N, et al. Efficacy and safety of an orally administered selective prostacyclin receptor agonist, selexipag, in Japanese patients with pulmonary arterial hypertension. Circ J. 2017;81(9):1360–1367.
  • AbuHalimeh BJ, Parambil JG, Tonelli AR. Different efficacy of inhaled and oral medications in pulmonary hypertension. Heart Lung. 2017;46(4):334–337.
  • Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12S):S56–S61.
  • Galiè N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2003;2(2):123–137.
  • Kingman M, Archer-Chicko C, Bartlett M, et al. Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension. Pulm Circ. 2017Jul-Sep;7(3):598–608. PubMed PMID: 28632002; eng
  • Hammer GP, du PrelJ-b, Blettner M, et al. Avoiding bias in observational studies: part 8 in a series of articles on evaluation of scientific publications. Dtsch Arztebl Int. 2009;106(41):664.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.